drugset
Drugs / 225Ac-J591
last change Jun 2026 re-read 9 days ago

225Ac-J591

Monoclonal antibody

Developed for
prostate cancer
Investigated by
Weill Medical College of Cornell University · United States Department of Defense · Merck Sharp & Dohme LLC · National Cancer Institute (NCI) · National Institutes of Health (NIH) · Prostate Cancer Foundation

Trials 5

today NCT04946370 · Ph 1/2 NCT04886986 · Ph 1 NCT04576871 · Ph 0 NCT04506567 · Ph 1/2 NCT03276572 · Ph 1
20182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT04576871 Oct 2020 → Aug 2023 prostate cancer Weill Medical College of Cornell University Completed No outcome recorded
Phase 12 trials
Phase 1 NCT04886986 Jun 2021 → Dec 2027 expected prostate cancer Weill Medical College of Cornell University Recruiting No outcome recorded
Phase 1 NCT03276572 Oct 2017 → Jan 2021 prostate cancer Weill Medical College of Cornell University Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT04946370 Aug 2021 → Oct 2027 expected prostate cancer Weill Medical College of Cornell University Recruiting No outcome recorded
Phase 1/2 NCT04506567 Aug 2020 → Jun 2025 overdue prostate cancer Weill Medical College of Cornell University Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as 225Ac-J591 “225Ac-J591” NCT04886986 ↗
4

NCT04946370 ↗

NCT03276572 ↗

NCT04576871 ↗

NCT04506567 ↗
Modality Monoclonal antibody “225Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225” PMID 37922438 ↗ Nov 2023
Route Intravenous “Intravenous administration.” NCT04886986 ↗